within Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GA03_Xylometazoline;

model Xylometazoline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 2.777777777777778e-06,
    adminDuration = 600,
    adminMass = 0.1 / 1000000,
    adminCount = 1,
    Vd = 0.0005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Xylometazoline</td></tr><tr><td>ATC code:</td><td>S01GA03</td></tr><td>route:</td><td>intranasal</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Xylometazoline is a topical nasal decongestant, acting as an alpha-adrenergic agonist. It is primarily used to relieve nasal congestion in conditions such as rhinitis, sinusitis, and the common cold. It is approved for short-term use and is widely available over the counter.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult population following intranasal administration. No published compartmental population pharmacokinetic studies exist for xylometazoline; values are inferred or estimated based on related information from similar topical nasal decongestants.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01GA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Xylometazoline;
